Bioprocessing Reagent Market Report 2026

The bioprocessing reagent market size has grown rapidly in recent years. It will grow from $9.03 billion in 2025 to $10.11 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to increasing adoption of cell culture techniques in biologics production, growth in monoclonal antibody manufacturing requiring specialized reagents, expansion of pharmaceutical and biotechnology research infrastructure, rising demand for vaccines driving large scale bioprocessing activities, early development of fermentation based industrial biotechnology processes.

The bioprocessing reagent market size is expected to see rapid growth in the next few years. It will grow to $16.06 billion by 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to rising demand for biosimilars and advanced biologics production, increasing adoption of automated and continuous bioprocessing systems, growing investment in cell and gene therapy manufacturing, expansion of personalized medicine requiring specialized bioprocessing workflows, increasing focus on scalable and cost efficient biomanufacturing processes. Major trends in the forecast period include ai driven bioprocess optimization for improved yield and reduced production variability, single use bioprocessing systems enabling flexible and contamination free manufacturing, continuous bioprocessing technologies enhancing production efficiency and scalability, advanced chromatography resin innovations for high purity biologics separation, sustainable bio-based reagent development for greener biomanufacturing processes.

The rising demand for monoclonal antibody and biologics production is expected to propel the growth of the bioprocessing reagent market going forward. Monoclonal antibodies and biologics are complex protein-based therapeutics derived from living cell systems that specifically target antigens to treat diseases such as cancer, autoimmune disorders, and neurological conditions. The growing demand for monoclonal antibody and biologics production is being driven by an increasing number of therapeutic approvals along with a strong late-stage clinical pipeline, thereby contributing to market expansion. Bioprocessing reagents are supporting monoclonal antibody and biologics production by enabling efficient cell culture processes, protein synthesis, and purification workflows that are essential for large-scale biologics manufacturing. For instance, in December 2024, according to the National Center for Biotechnology Information, a US-based biomedical research platform, 21 antibody therapeutics received first approvals in 2024 compared to 16 approvals in 2023, indicating a year-on-year increase in biologics commercialization activity. Therefore, the rising demand for monoclonal antibody and biologics production is propelling the growth of the bioprocessing reagent market.

Leading companies operating in the bioprocessing reagent market are focusing on advancing high-performance single-use technologies, such as pre-sterilized, disposable bioprocessing reagents, to enhance manufacturing flexibility, reduce contamination risks, and lower capital expenditure. Single-use bioprocessing reagents are ready-to-use, disposable chemical and biological components designed for one-time application in upstream and downstream processing, eliminating the need for cleaning validation and reducing turnaround time. For example, in October 2023, Thermo Fisher Scientific Inc., a US-based biotechnology company, introduced its Gibco CTS Detachable Dynabeads platform, a next-generation cell separation technology designed for cell therapy manufacturing. The platform enables gentle bead detachment to improve cell viability, supports closed-system processing to reduce contamination risk, and enhances scalability for commercial production. This launch reflects strong supplier focus on reducing operational costs while improving process efficiency and compliance in advanced biomanufacturing environments.

In March 2024, Ampersand Capital Partners, a US-based private equity firm focused on healthcare and life sciences investments, acquired Biologos LLC for an undisclosed amount. Through this acquisition, Ampersand Capital Partners intends to strengthen its presence in the bioprocessing sector by broadening product offerings, improving manufacturing capabilities, and accelerating global expansion. Biologos LLC is a US-based biotechnology manufacturing company with significant expertise in bioprocessing reagents, offering a wide range of standard and custom sterile-filtered biological solutions.

Major companies operating in the bioprocessing reagent market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, FUJIFILM Corporation, Corning Incorporated, Lonza Group, Avantor Inc., Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne, Repligen Corporation, Promega Corporation, Takara Bio, MP Biomedicals, ITW, Creative Bioarray, PromoCell, Rockland Immunochemicals, Solis BioDyne, Nippon Genetics, HiMedia Laboratories, Capricorn Scientific, Serana Europe, ZenBio.

North America was the largest region in the bioprocessing reagent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioprocessing reagent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bioprocessing reagent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioprocessing reagent market consists of sales of single-use bioreactor bags, recombinant proteins, cell dissociation reagents, transfection reagents, viral vectors, affinity ligands, membrane adsorbers, and endotoxin removal kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.